Karolinska Development
 

View full portfolio and sort by:

   

Inflammation

Inflammation-driven autoimmune reaction causes several diseases such as rheumatoid arthritis. The need to alleviate such reactions as well as autoimmune inflammation in transplantation is significant. Several of the projects within Karolinska Development's inflammation portfolio have first-in-class potential.

 

Concept Development Lead Discovery Lead Optimization Preclinical Development Phase I Phase II Phase III Launch

NovaSAID AB

ProNoxis AB

First In Class Potential

NovaSAID AB

NovaSAID is developing new drugs for the treatment of inflammatory diseases, such as rheumatoid arthritis and osteoarthritis.

www.novasaid.se
 
First In Class Potential

ProNoxis AB

ProNoxis is developing new small molecules for the treatment of chronic inflammation, such as rheumatoid arthritis, multiple sclerosis and abdominal inflammation.

www.pronoxis.se